

Emanuele Bosi

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/3530912/emanuele-bosi-publications-by-year.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

58
papers

3,565
citations

25
h-index

59
g-index

59
ext. papers

4,730
ext. citations

6.8
avg. IF

4.67
L-index

#	Paper	IF	Citations
58	Exocrine pancreas function is impaired in adult relatives of patients with type 1 diabetes. <i>Acta Diabetologica</i> , 2021 , 1	3.9	0
57	No evidence of long-term disruption of glycometabolic control after SARS-CoV-2 infection. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021 ,	5.6	9
56	Clinical factors associated with death in 3044 COVID-19 patients managed in internal medicine wards in Italy: results from the SIMI-COVID-19 study of the Italian Society of Internal Medicine (SIMI). <i>Internal and Emergency Medicine</i> , 2021 , 16, 1005-1015	3.7	16
55	Real-world performance of the MiniMed670G system in Europe. <i>Diabetes, Obesity and Metabolism</i> , 2021 , 23, 1942-1949	6.7	8
54	Epicardial adipose tissue characteristics, obesity and clinical outcomes in COVID-19: A post-hoc analysis of a prospective cohort study. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2021 , 31, 2156-2164	4.5	6
53	Impaired exocrine pancreatic function in different stages of type 1 diabetes. <i>BMJ Open Diabetes Research and Care</i> , 2021 , 9,	4.5	3
52	Structured self-monitoring of blood glucose is associated with more appropriate therapeutic interventions than unstructured self-monitoring: A novel analysis of data from the PRISMA trial. <i>Diabetes Research and Clinical Practice</i> , 2021 , 181, 109070	7.4	2
51	Pulmonary Vascular Thrombosis in COVID-19 Pneumonia. <i>Journal of Cardiothoracic and Vascular Anesthesia</i> , 2021 , 35, 3631-3641	2.1	16
50	Transcutaneous electrical stimulation therapy and genetic analysis in Dercum's disease: A pilot study.. <i>Medicine (United States)</i> , 2021 , 100, e28360	1.8	
49	Predicting Factors Associated with Hypoglycemia Reduction with Automated Predictive Insulin Suspension in Patients at High Risk of Severe Hypoglycemia: An Analysis from the SMILE Randomized Trial. <i>Diabetes Technology and Therapeutics</i> , 2020 , 22, 681-685	8.1	0
48	Early predictors of clinical outcomes of COVID-19 outbreak in Milan, Italy. <i>Clinical Immunology</i> , 2020 , 217, 108509	9	167
47	Expression of glucose transporters in duodenal mucosa of patients with type 1 diabetes. <i>Acta Diabetologica</i> , 2020 , 57, 1367-1373	3.9	2
46	Cervix neuroendocrine carcinoma presenting with severe hypokalemia and Cushing's syndrome. <i>Endocrine</i> , 2020 , 67, 318-320	4	0
45	Residual clinical damage after COVID-19: A retrospective and prospective observational cohort study. <i>PLoS ONE</i> , 2020 , 15, e0239570	3.7	69
44	Biobanking for COVID-19 research. <i>Panminerva Medica</i> , 2020 ,	2	21
43	Introducing the Endotype Concept to Address the Challenge of Disease Heterogeneity in Type 1 Diabetes. <i>Diabetes Care</i> , 2020 , 43, 5-12	14.6	111
42	Reduced PD-1 expression on circulating follicular and conventional FOXP3 Treg cells in children with new onset type 1 diabetes and autoantibody-positive at-risk children. <i>Clinical Immunology</i> , 2020 , 211, 108319	9	11

41	Antibody response to multiple antigens of SARS-CoV-2 in patients with diabetes: an observational cohort study. <i>Diabetologia</i> , 2020 , 63, 2548-2558	10.3	53
40	Interferon β 1a (IFN β 1a) in COVID-19 patients (INTERCOP): study protocol for a randomized controlled trial. <i>Trials</i> , 2020 , 21, 939	2.8	14
39	Enrichment of Tc1 cells and T cell resistance to suppression are associated with dysglycemia in the visceral fat in human obesity. <i>BMJ Open Diabetes Research and Care</i> , 2020 , 8,	4.5	1
38	Randomized 52-week Phase 2 Trial of Albiglutide Versus Placebo in Adult Patients With Newly Diagnosed Type 1 Diabetes. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020 , 105,	5.6	7
37	Clinical Targets for Continuous Glucose Monitoring Data Interpretation: Recommendations From the International Consensus on Time in Range. <i>Diabetes Care</i> , 2019 , 42, 1593-1603	14.6	998
36	Efficacy and safety of suspend-before-low insulin pump technology in hypoglycaemia-prone adults with type 1 diabetes (SMILE): an open-label randomised controlled trial. <i>Lancet Diabetes and Endocrinology</i> , 2019 , 7, 462-472	18.1	53
35	Low-Dose Anti-Thymocyte Globulin Preserves C-Peptide, Reduces HbA _{1c} , and Increases Regulatory to Conventional T-Cell Ratios in New-Onset Type 1 Diabetes: Two-Year Clinical Trial Data. <i>Diabetes</i> , 2019 , 68, 1267-1276	0.9	45
34	Abnormal neutrophil signature in the blood and pancreas of presymptomatic and symptomatic type 1 diabetes. <i>JCI Insight</i> , 2018 , 3,	9.9	50
33	Study of MiniMed 640G Insulin Pump with SmartGuard in Prevention of Low Glucose Events in Adults with Type 1 Diabetes (SMILE): Design of a Hypoglycemia Prevention Trial with Continuous Glucose Monitoring Data as Outcomes. <i>Diabetes Technology and Therapeutics</i> , 2018 , 20, 758-766	8.1	5
32	Role of Continuous Glucose Monitoring in Clinical Trials: Recommendations on Reporting. <i>Diabetes Technology and Therapeutics</i> , 2017 , 19, 391-399	8.1	36
31	Impact of Age and Antibody Type on Progression From Single to Multiple Autoantibodies in Type 1 Diabetes Relatives. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2017 , 102, 2881-2886	5.6	27
30	Duodenal Mucosa of Patients With Type 1 Diabetes Shows Distinctive Inflammatory Profile and Microbiota. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2017 , 102, 1468-1477	5.6	80
29	The evolving frontier of diabetes therapy: The renaissance of glycemology. <i>Diabetes Research and Clinical Practice</i> , 2016 , 118, 168-71	7.4	3
28	The Burden of Structured Self-Monitoring of Blood Glucose on Diabetes-Specific Quality of Life and Locus of Control in Patients with Noninsulin-Treated Type 2 Diabetes: The PRISMA Study. <i>Diabetes Technology and Therapeutics</i> , 2016 , 18, 421-8	8.1	15
27	Pharmacogenetic influence of eNOS gene variant on endothelial and glucose metabolism responses to L-arginine supplementation: Post hoc analysis of the L-arginine trial. <i>Metabolism: Clinical and Experimental</i> , 2015 , 64, 1582-91	12.7	7
26	Clinical Utility of SMBG: Recommendations on the Use and Reporting of SMBG in Clinical Research. <i>Diabetes Care</i> , 2015 , 38, 1627-33	14.6	20
25	Successful Treatment of Dercum's Disease by Transcutaneous Electrical Stimulation: A Case Report. <i>Medicine (United States)</i> , 2015 , 94, e950	1.8	12
24	Low-dose oteeliximumab anti-CD3 monoclonal antibody DEFEND-1 study: results of the randomized phase III study in recent-onset human type 1 diabetes. <i>Diabetes Care</i> , 2014 , 37, 2746-54	14.6	79

23	Identification of novel genetic Loci associated with thyroid peroxidase antibodies and clinical thyroid disease. <i>PLoS Genetics</i> , 2014 , 10, e1004123	6	122
22	Improvement in clinical symptoms of scleredema diabeticorum by frequency-modulated electromagnetic neural stimulation: a case report. <i>Diabetes Care</i> , 2014 , 37, e233-4	14.6	7
21	Prospective, randomized trial on intensive SMBG management added value in non-insulin-treated T2DM patients (PRISMA): a study to determine the effect of a structured SMBG intervention. <i>Acta Diabetologica</i> , 2013 , 50, 663-72	3.9	18
20	Intensive structured self-monitoring of blood glucose and glycemic control in noninsulin-treated type 2 diabetes: the PRISMA randomized trial. <i>Diabetes Care</i> , 2013 , 36, 2887-94	14.6	78
19	Reduction of circulating neutrophils precedes and accompanies type 1 diabetes. <i>Diabetes</i> , 2013 , 62, 2072-3	14.6	140
18	Response to comment on: Bosi et al. Intensive structured self-monitoring of blood glucose and glycemic control in noninsulin-treated type 2 diabetes: the PRISMA randomized trial. <i>Diabetes Care</i> 2013;36:2887-2894. <i>Diabetes Care</i> , 2013 , 36, e218	14.6	2
17	Alogliptin as a third oral antidiabetic drug in patients with type 2 diabetes and inadequate glycaemic control on metformin and pioglitazone: a 52-week, randomized, double-blind, active-controlled, parallel-group study. <i>Diabetes, Obesity and Metabolism</i> , 2011 , 13, 1088-96	6.7	62
16	La malattia diabetica nell'anziano. <i>Rivista Italiana Della Medicina Di Laboratorio</i> , 2011 , 7, 80-82	1.1	
15	Time for testing incretin therapies in early type 1 diabetes?. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2010 , 95, 2607-9	5.6	27
14	Frequency-modulated electromagnetic neural stimulation enhances cutaneous microvascular flow in patients with diabetic neuropathy. <i>Journal of Diabetes and Its Complications</i> , 2009 , 23, 46-8	3.2	14
13	Incretin-based therapies in type 2 diabetes: a review of clinical results. <i>Diabetes Research and Clinical Practice</i> , 2008 , 82 Suppl 2, S102-7	7.4	21
12	Effects of vildagliptin on glucose control over 24 weeks in patients with type 2 diabetes inadequately controlled with metformin. <i>Diabetes Care</i> , 2007 , 30, 890-5	14.6	365
11	Increased intestinal permeability precedes clinical onset of type 1 diabetes. <i>Diabetologia</i> , 2006 , 49, 2824-3	17.3	269
10	Effectiveness of frequency-modulated electromagnetic neural stimulation in the treatment of painful diabetic neuropathy. <i>Diabetologia</i> , 2005 , 48, 817-23	10.3	73
9	Gluten-free diet in subjects at risk for type 1 diabetes: a tool for delaying progression to clinical disease?. <i>Advances in Experimental Medicine and Biology</i> , 2005 , 569, 157-8	3.6	4
8	Fulminant autoimmune Type 1 diabetes during interferon-alpha therapy: a case of Th1-mediated disease?. <i>Diabetic Medicine</i> , 2001 , 18, 329-32	3.5	37
7	Autoantibody response to islet transplantation in type 1 diabetes. <i>Diabetes</i> , 2001 , 50, 2464-71	0.9	106
6	Predizione e prospettive di prevenzione del diabete di tipo 1. <i>L'Endocrinologo</i> , 2001 , 2, 119-124	0	

5	Comparison of tissue transglutaminase-specific antibody assays with established antibody measurements for coeliac disease. <i>Journal of Autoimmunity</i> , 1999 , 12, 51-6	15.5	92
4	Gluten: is it also a determinant of islet autoimmunity?. <i>Diabetes/metabolism Reviews</i> , 1998 , 14, 258-9		4
3	Heterogeneity of autoantibodies in stiff-man syndrome. <i>Annals of Neurology</i> , 1993 , 34, 57-64	9.4	106
2	Progression to type I diabetes in autoimmune endocrine patients with islet cell antibodies. <i>Diabetes</i> , 1991 , 40, 977-84	0.9	46
1	Novel considerations on the antibody/autoantigen system in type I (insulin-dependent) diabetes mellitus. <i>Annals of Medicine</i> , 1991 , 23, 453-61	1.5	25